EDN1 and breast carcinoma: For instance, atrasentan reduces breast cancer cell invasiveness induced by hypoxia-mediated ET-1 secretion [243] and potentiates the anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells [244].